Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression

NCT06926660 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06926660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
July 18, 2025
Completion date
August 14, 2026
Enrollment
492 (actual)
Sites
157

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease